Illumina, Inc. $ILMN Stock Holdings Boosted by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management increased its Illumina stake by 52.5% in the third quarter, owning 469,340 shares valued at approximately $128.4 million. Institutional investors and hedge funds collectively own 89.42% of the company.
• Illumina reported quarterly earnings of $1.31 per share, exceeding the $1.23 consensus estimate, while revenue rose 9.4% year over year to $1.16 billion. The company reaffirmed fiscal 2026 EPS guidance of $5.30–$5.40.
• Analyst sentiment remains mixed: several firms raised price targets, but the consensus rating is still “Hold” with an average target of $231.88. Insiders sold more than 2 million shares worth approximately $436.5 million over the past three months.

Robeco Institutional Asset Management B.V. grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 52.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 469,340 shares of the life sciences company's stock after buying an additional 161,555 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.31% of Illumina worth $128,449,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Baker Tilly Wealth Management LLC grew its holdings in Illumina by 3.3% during the third quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company's stock valued at $355,000 after purchasing an additional 42 shares during the period. Elevation Wealth Partners LLC increased its stake in Illumina by 19.7% in the third quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company's stock valued at $80,000 after purchasing an additional 48 shares in the last quarter. IFP Advisors Inc increased its stake in Illumina by 2.9% in the third quarter. IFP Advisors Inc now owns 1,986 shares of the life sciences company's stock valued at $544,000 after purchasing an additional 56 shares in the last quarter. Valeo Financial Advisors LLC raised its holdings in Illumina by 1.5% in the third quarter. Valeo Financial Advisors LLC now owns 4,031 shares of the life sciences company's stock worth $1,103,000 after purchasing an additional 61 shares during the period. Finally, Robertson Stephens Wealth Management LLC raised its holdings in Illumina by 0.9% in the third quarter. Robertson Stephens Wealth Management LLC now owns 6,748 shares of the life sciences company's stock worth $1,847,000 after purchasing an additional 63 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Performance

Shares of ILMN opened at $282.86 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a twelve month low of $94.00 and a twelve month high of $309.35. The firm's 50 day moving average price is $239.24 and its two-hundred day moving average price is $189.54. The firm has a market cap of $42.71 billion, a P/E ratio of 52.77, a PEG ratio of 3.79 and a beta of 1.41.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of recent analyst reports. Piper Sandler lifted their price target on shares of Illumina from $225.00 to $305.00 and gave the stock an "overweight" rating in a research report on Monday, September 28th. Royal Bank Of Canada upped their price objective on shares of Illumina from $230.00 to $310.00 and gave the company an "outperform" rating in a research report on Monday, October 5th. Canaccord Genuity Group raised their price objective on Illumina from $205.00 to $300.00 and gave the stock a "hold" rating in a research note on Monday. Wall Street Zen upgraded Illumina from a "hold" rating to a "buy" rating in a report on Sunday, October 11th. Finally, Barclays lifted their target price on Illumina from $160.00 to $200.00 and gave the stock an "underweight" rating in a report on Wednesday, October 7th. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $231.88.

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the sale, the director owned 2,372,694 shares of the company's stock, valued at $474,776,069.40. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last three months, insiders sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.